Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Cash from Investing Activities data on record, last reported at $81.6 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 130.33% year-over-year to $81.6 million; the TTM value through Dec 2025 reached $290.0 million, up 231.97%, while the annual FY2025 figure was $290.0 million, 231.97% up from the prior year.
  • Cash from Investing Activities reached $81.6 million in Q4 2025 per SNDX's latest filing, up from $72.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $94.1 million in Q1 2025 and bottomed at -$269.0 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is -$2.0 million, with a median of $20.8 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: soared 689.97% in 2023, then tumbled 1551.15% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$60.0 million in 2021, then plummeted by 129.55% to -$137.6 million in 2022, then soared by 88.16% to -$16.3 million in 2023, then crashed by 1551.15% to -$269.0 million in 2024, then skyrocketed by 130.33% to $81.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $81.6 million in Q4 2025, $72.4 million in Q3 2025, and $41.9 million in Q2 2025.